Intensity Therapeutics, Inc. (INTS) Stock Price & Analysis
Intensity Therapeutics, Inc. (INTS) fell 0.84% to USD 4.45 as of July 25, 2026 at 09:19 UTC, according to Nexqual real-time market data.
INTS last closed at USD 4.49; the session ranged USD 4.4–4.49 on volume of 2,645 shares. Market capitalization is $12.03M, with a 52-week range of USD 3.51–43.5 (NCM). Source: Nexqual, July 25, 2026 at 09:19 UTC.
Key Statistics (as of July 25, 2026 at 09:19 UTC)
| Price | USD 4.45 |
|---|---|
| Change | ▼ 0.84% (down) |
| Previous Close | USD 4.49 |
| Open | USD 4.49 |
| Day Range | USD 4.4 – 4.49 |
| 52-Week Range | USD 3.51 – 43.5 |
| Volume | 2,645 shares |
| Market Cap | $12.03M |
| Exchange | NCM |
Technical Analysis (INTS)
Nexqual's technical model rates INTS "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 09:19 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.91 (neutral) |
| vs SMA50 | Above (USD 4.34) |
| MACD | 0.06 (positive) |
Analyst Ratings (INTS)
Wall Street analysts rate INTS "None" based on 5 analysts, with a mean price target of USD 24.8 (range USD 12–32), per Nexqual as of July 25, 2026 at 09:19 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 24.8 |
| High Target | USD 32 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (INTS)
| EPS Estimate | USD -0.77 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.96 vs est -1.09 ▲ beat |
| 2025-09-30 | USD -1.5 vs est -1.5 ▲ beat |
| 2025-06-30 | USD -3.25 vs est -4.5 ▲ beat |
Source: Nexqual, July 25, 2026 at 09:19 UTC.
Financials & Fundamentals (INTS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -207.37% |
| Debt / Equity | 1.02 |
| Current Ratio | 4.86 |
| Total Cash | $10.24M |
| Total Debt | $102,000 |
| Free Cash Flow | $-5.32M |
Source: Nexqual, July 25, 2026 at 09:19 UTC.
Financial Health Score (INTS)
Nexqual rates Intensity Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 09:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$9M |
| Efficiency | Critical — ROE -207%, ROA -90.4% |
Ownership (INTS)
| Insider Ownership | +4.55% |
|---|---|
| Institutional Ownership | +7.01% |
| Shares Outstanding | 2.70M |
| Float | 2.48M |
| Short % of Float | +6.30% |
Source: Nexqual, July 25, 2026 at 09:19 UTC.
Leadership (INTS)
Intensity Therapeutics, Inc. is led by Lewis H. Bender M.A., M.B.A., M.S. (age 66), Founder, President, CEO & Chairman of the Board, per Nexqual as of July 25, 2026 at 09:19 UTC.
| Founder, President, CEO & Chairman of the Board | Lewis H. Bender M.A., M.B.A., M.S. (age 66) |
|---|---|
| Chief Financial Officer | Joseph Talamo (age 56) |
| Executive Vice President of Corporate Finance | James M. Ahlers (age 61) |
Major Backers & Investors (INTS)
Notable institutional backers of Intensity Therapeutics, Inc. include Sapient Capital LLC, Nano Cap New Millennium Growth Fund L P, Rothschild Wealth, LLC, according to Nexqual as of July 25, 2026 at 09:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sapient Capital LLC | 0.96% |
| Nano Cap New Millennium Growth Fund L P | 0.92% |
| Rothschild Wealth, LLC | 0.86% |
| FNY Investment Advisers, LLC | 0.81% |
| Fidelity | 0.74% |
| Mesirow Financial Investment Management, Inc. | 0.52% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.58% |
| Geode Capital | 0.96% |
Source: Nexqual, July 25, 2026 at 09:19 UTC.
From Intensity Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- If we successfully execute the agreed-upon plan, we expect that the CMC portion of a New Drug Application ("NDA") should be acceptable to the FDA for product approval and registration (subject to final NDA review).
- Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules.
- Our Proprietary Drug Discovery platform, DfuseRx SM Since our inception, we have conducted research using our discovery platform.
- Our technology platform allows us to identify novel product formulations and test the products' activity in animal or test tube models of cancer.
Partnerships
- In 2019, as part of our IT-01 Study, we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid malignancies, including pancreatic, bile duct, squamous cell and non-MSI high colon cancers.
- In 2020, as part of our IT-01 Study, we entered into an agreement with BMS to evaluate the safety and efficacy of INT230-6 with Yervoy ® (ipilimumab), BMS's CTLA-4 immune checkpoint inhibitor, in patients with breast (17%), liver (5%), and advanced sarcoma cancer (78%).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MSAI | MultiSensor AI Holdings, Inc. | USD 4.84 | ▼ 7.28% |
| FEMY | Femasys Inc. | USD 3.71 | ▲ 5.4% |
| AIRE | reAlpha Tech Corp. | USD 1.38 | ▲ 8.66% |
| IXHL | Incannex Healthcare Inc. | USD 2.95 | ▼ 5.45% |
| PCSA | Processa Pharmaceuticals, Inc. | USD 2.6 | ▲ 2.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:19 UTC. This page is informational and not investment advice.